MajesTEC-3
A bispecific plus daratumumab cut the risk of progression by more than 80% versus standard doublets, bringing bispecifics to second line.
PFS median not reached vs 18.1 months; 36-month PFS 83.4% vs 29.7% (HR ~0.17). Approved 5 March 2026 for ≥1 prior line; EU approval followed. Infection prophylaxis mandatory.
- 83.4 vs 29.7 out of 100 alive without the cancer growing at 36 months with Teclistamab + daratumumab compared with Dara-Pd / Dara-Vd; 53.7 more per 100.
- Roughly one extra person helped for every 2 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 83 percent lower chance of the event at any given time (hazard ratio 0.17).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after 1-3 prior lines: teclistamab + daratumumab vs Dara-Pd or Dara-Vd. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialMajesTEC-1
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PairingCaution: T-cell redirectors and infections
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PairingBCMA-directed therapy → GPRC5D-directed therapy
Shares MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma, Teclistamab, Multiple myeloma.
- PersonSaad Z. Usmani
Shares Teclistamab, Daratumumab, Multiple myeloma.
- PersonSundar Jagannath
Shares Teclistamab, Multiple myeloma.
- TrialCEPHEUS
Shares Daratumumab, Multiple myeloma.
- IdeaMRD-guided treatment-free intervals in myeloma
Shares Daratumumab, Multiple myeloma.
- TermMGUS and smouldering myeloma
Shares Daratumumab, Multiple myeloma.